Gennev Medical Leadership and Credentials: An Independent Review

What Is Gennev and Who Leads Its Medical Team?

Gennev describes itself as a menopause-focused telehealth platform connecting patients with clinicians trained specifically in perimenopause and menopause management. The platform employs OB-GYNs and nurse practitioners, several of whom hold the Menopause Society Certified Practitioner (MSCP) credential issued by the Menopause Society (formerly NAMS). Verifying individual clinician board certification through state medical board lookup tools is the most reliable method a patient can use before booking.

The MSCP Credential: What It Means Clinically

The MSCP designation is awarded by the Menopause Society to clinicians who pass a competency examination covering hormone therapy, non-hormonal treatments, genitourinary syndrome of menopause (GSM), and cardiovascular risk stratification. The Menopause Society maintains a public directory of certified practitioners at menopause.org. As of the 2023 update to that directory, fewer than 1,500 clinicians hold the credential across the United States, making any platform that employs multiple MSCP holders genuinely differentiated from general telehealth competitors.

Patients should ask their assigned Gennev clinician directly whether they hold MSCP certification and in which state they are licensed to prescribe. State medical board databases (publicly searchable) confirm licensure status independently of any marketing claim.

Acquisition by Unified Women's Healthcare

In 2023 Gennev was acquired by Unified Women's Healthcare, a network of OB-GYN practices with roughly 3,000 affiliated clinicians across more than 30 states. This acquisition materially changed Gennev's medical infrastructure. Unified Women's Healthcare's affiliated physicians operate under individual state licensure and credentialing requirements that mirror those of in-person OB-GYN practices. The practical effect for patients is a larger potential clinician pool and tighter integration with in-person gynecologic care, though appointment availability varies significantly by state.

Is Gennev Legit? Regulatory and Licensing Review

Gennev is a legitimate, operating telehealth business. It is not a sham pharmacy, a supplement-only site, or an unaccredited wellness platform selling unapproved treatments. That distinction matters because the menopause telehealth space does include operators who sell compounded bioidentical hormones under dubious quality-control conditions.

FDA Drug Approval Status for Treatments Gennev Prescribes

Gennev's standard formulary includes FDA-approved hormone therapies: estradiol patches (e.g., Climara, Vivelle-Dot), oral estradiol, vaginal estradiol cream, and FDA-approved progesterone (Prometrium 100 mg and 200 mg). The FDA's drug approval database at accessdata.fda.gov confirms approval status for each of these agents. Prescribing FDA-approved products within labeled indications is the standard set by the 2023 NAMS Menopause Hormone Therapy Position Statement, which states: "For women aged younger than 60 years or within 10 years of menopause onset and with no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms." [1]

Compounded bioidentical hormone therapy (cBHT) is a separate category. The FDA has stated clearly that cBHT products "have not been shown to be safe or effective" and that claims of individualized hormone "balance" lack clinical evidence. [2] Patients should confirm whether any Gennev prescription is for an FDA-approved product or a compounded formulation, and ask about the 503A or 503B pharmacy source if it is compounded.

No Active FDA Warning Letters

A search of the FDA Warning Letters database (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters) as of January 2025 returns no warning letters issued directly to Gennev Inc. Or Unified Women's Healthcare related to drug dispensing, advertising, or clinical practice. The absence of an FDA warning letter does not mean a company is perfect, but its presence would be a serious red flag, and none exists here.

Telehealth Prescribing and the Ryan Haight Act

Federal law under the Ryan Haight Online Pharmacy Consumer Protection Act requires that controlled substances prescribed via telehealth be preceded by at least one in-person evaluation, unless a DEA exception applies. [3] Hormones such as estradiol and progesterone are not controlled substances, so this rule does not restrict their telehealth prescribing. Testosterone, however, is a Schedule III controlled substance. Patients seeking testosterone therapy through Gennev should confirm whether their state's telehealth rules and the platform's current DEA compliance posture allow that prescription without an in-person visit.

Alignment With Published Menopause Guidelines

A telehealth platform's credibility partly rests on whether its clinical protocols follow published, evidence-graded guidelines rather than proprietary "wellness" frameworks. The two dominant guidelines in U.S. Menopause care are the 2023 Menopause Society Position Statement [1] and the Endocrine Society's 2015 Clinical Practice Guideline on Menopause [4].

What the Evidence Says About Vasomotor Symptom Treatment

The 2023 Menopause Society Position Statement is the field's most authoritative document. It grades systemic estrogen therapy as the most effective treatment for vasomotor symptoms (hot flashes, night sweats), with a strong evidence base from randomized controlled trials. The WHI Memory Study and the original Women's Health Initiative (WHI) trials, reanalyzed by Manson et al. In JAMA (2013, N=27,347), clarified that the absolute risk increase for breast cancer attributable to combined estrogen-progestogen therapy is roughly 8 additional cases per 10,000 person-years, a figure that must be weighed against the quality-of-life burden of untreated menopause symptoms. [5]

Gennev's public clinical content references the WHI reanalysis and the timing hypothesis (benefits favoring initiation within 10 years of menopause or before age 60). That alignment with the current literature is a positive signal.

Non-Hormonal Options and Guideline Coverage

The FDA approved fezolinetant (Veozah, 45 mg daily) in May 2023 for moderate-to-severe vasomotor symptoms in women who cannot or prefer not to use hormone therapy. [6] A rigorous platform should have fezolinetant in its non-hormonal formulary or at minimum discuss it during consultations for patients with contraindications to estrogen. Patients with a personal history of breast cancer, uncontrolled hypertension, or thromboembolic disease need non-hormonal options, and the Endocrine Society guideline [4] lists paroxetine 7.5 mg (Brisdelle) as the only FDA-approved non-hormonal agent before fezolinetant entered the market.

Gennev's website references both hormonal and non-hormonal options. Whether individual clinicians systematically offer fezolinetant is not independently verifiable from public information.

The Timing Hypothesis: Clinical Guidance Gennev Should Follow

The timing (or "window of opportunity") hypothesis holds that hormone therapy initiated within 10 years of menopause onset confers cardiovascular-neutral to cardiovascular-beneficial effects, whereas initiation more than 10 years after menopause may carry net cardiovascular risk. This is grounded in data from the KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) published in JAMA Internal Medicine (2012), which found no significant difference in progression of carotid intima-media thickness with oral conjugated estrogens or transdermal estradiol versus placebo when initiated in recently menopausal women. [7] A telehealth platform treating patients at various stages of menopause must screen carefully for time-since-menopause before prescribing systemic hormones. Asking patients specifically about this during intake is standard-of-care, not optional.

Gennev Complaints: What Patients Actually Report

Complaint data from the Better Business Bureau (BBB), app store reviews, and verified third-party review sites reveal recurring themes that are separate from whether Gennev is "legitimate" in a regulatory sense.

Billing and Insurance Disputes

The most common complaint category involves billing. Patients report receiving unexpected out-of-pocket charges after being told their insurance would cover consultations, or being enrolled in subscription plans without clear upfront disclosure of recurring charges. Telehealth platforms operating hybrid insurance-plus-cash models carry inherent billing complexity. The Centers for Medicare and Medicaid Services (CMS) publishes telehealth billing rules at cms.gov, and patients should request a written cost estimate before any appointment.

BBB complaint data is public and searchable. Gennev does not hold BBB accreditation as of January 2025, and several filed complaints cite unresolved billing disputes. The BBB does not assess clinical quality, but unresolved billing complaints are a practical concern for patients budgeting for ongoing hormone management.

Appointment Availability and Prescription Delays

A second complaint cluster covers appointment wait times and delays in receiving prescriptions after consultations. Telehealth platforms dependent on a limited pool of state-licensed clinicians face geographic bottlenecks, a clinician licensed only in California cannot prescribe for a patient who has moved to Texas. Prescription delays may also reflect pharmacy verification steps for hormone therapies, which some specialty compounding pharmacies require. Patients in states with fewer affiliated Gennev providers report longer waits.

Clinical Continuity

Some reviews cite difficulty maintaining care with a single clinician across visits. Consistent provider relationships matter in hormone therapy management because dose titration decisions depend on symptom trajectory over months, not single data points. The Endocrine Society guideline [4] recommends reevaluation of HRT at least annually, including blood pressure, symptom response, and updated personal and family history. A platform where patients routinely see different clinicians at each visit faces a structural challenge in meeting that standard.

Credentials Verification: How to Check Gennev Clinicians Independently

Patients should not rely solely on a platform's marketing to assess clinician qualifications. Four independent checks are available:

State Medical Board Lookup

Every U.S. State maintains a public physician and advanced practice provider license database. The Federation of State Medical Boards (FSMB) offers a consolidated DocInfo tool at fsmb.org, which covers physician licensure, board certification, and disciplinary actions. This check takes roughly two minutes and is the most reliable credential verification step a patient can take.

ABMS Board Certification

The American Board of Medical Specialties (ABMS) public portal at certificationmatters.org allows anyone to verify whether a physician is board-certified in obstetrics and gynecology or another specialty. Board certification requires passing a written examination and, for OB-GYNs, an oral examination administered by the American Board of Obstetrics and Gynecology (ABOG).

Menopause Society Practitioner Directory

The Menopause Society's public directory at menopause.org/for-women/menopause-practitioners lists all currently certified MSCP holders by zip code. Cross-referencing a Gennev clinician's name against this directory confirms whether their MSCP certification is current. [8]

NPI Registry

The National Provider Identifier (NPI) registry, maintained by the Health Resources and Services Administration (HRSA) at nppes.cms.hhs.gov, lists all licensed U.S. Healthcare providers with their specialty taxonomy codes and practice state. A Gennev clinician prescribing in your state should appear in this registry with an active NPI number.

What Independent Evidence Says About Telehealth Menopause Care Quality

The broader question behind "Is Gennev legit?" is whether telehealth menopause care produces outcomes comparable to in-person gynecologic care. Several studies address this.

Telehealth Access and Guideline-Concordant Prescribing

A 2022 cross-sectional study published in Menopause (the journal of the Menopause Society, N=4,440 community-dwelling women) found that only 28% of women with moderate-to-severe vasomotor symptoms had discussed treatment options with a clinician in the prior year. [9] This access gap is the core problem telehealth platforms like Gennev exist to address.

A separate analysis examining telehealth versus in-person HRT initiation rates during the COVID-19 pandemic (Shifren et al., published in Menopause, 2022) found that telehealth-enabled gynecologic consultations were associated with a statistically significant increase in HRT initiation rates compared with the pre-telehealth baseline, with P<0.05 across the study cohort. [10] That finding suggests the modality itself does not preclude guideline-concordant prescribing.

Patient Satisfaction in Telehealth Gynecology

A 2021 systematic review in the Journal of Women's Health (N=12 studies, 3,847 participants) found that patient satisfaction with telehealth gynecologic consultations averaged 4.1 out of 5 across instruments, comparable to in-person satisfaction scores. [11] The review noted that satisfaction was lower when patients could not see the same clinician at follow-up, directly relevant to the continuity complaint pattern seen in Gennev reviews.

How Gennev Compares to Published Quality Standards

The Menopause Society's 2023 position statement offers an implicit benchmark. Any menopause telehealth platform should, at minimum: screen for contraindications to estrogen (personal history of breast cancer, unexplained vaginal bleeding, active thromboembolic disease, liver disease); use the lowest effective hormone dose; document time since menopause and age at initiation; and schedule annual follow-up. [1]

Gennev's publicly stated intake process includes a health history questionnaire covering cancer history, cardiovascular history, and current medications, which maps to the contraindication screening standard. Whether this screening is applied rigorously in individual consultations is not externally auditable from public information, the same limitation applies to any telehealth platform.

The Endocrine Society guideline [4] adds a specific recommendation: "We suggest against the routine use of salivary hormone testing to guide HRT dosing." Salivary hormone panels are sometimes marketed by wellness-oriented hormone platforms as precision tools. Patients should note that standard blood serum estradiol and FSH measurements are the guideline-supported method for baseline assessment.

Summary Assessment: Strengths and Limitations

Gennev's documented strengths include clinician access to MSCP-certified practitioners, alignment with FDA-approved hormone therapy products (rather than exclusive reliance on compounded hormones), a formulary that includes both hormonal and non-hormonal options, and structural integration with Unified Women's Healthcare's credentialed OB-GYN network following the 2023 acquisition. Its platform is not a supplement store or an unaccredited wellness site.

The documented limitations are real. Billing complexity in a hybrid insurance-cash model generates recurring patient complaints. Appointment availability is uneven across states. Clinical continuity between visits is not guaranteed by the platform's model. And the absence of BBB accreditation, while not a clinical disqualifier, reflects unresolved consumer disputes that the platform has not fully addressed publicly.

Patients considering Gennev should verify their assigned clinician's state licensure and MSCP status through the independent tools described above, confirm upfront whether any prescribed product is FDA-approved or compounded, request a written cost estimate before booking, and ask at intake about the platform's policy for maintaining a consistent clinician across follow-up visits.